Synta Pharmaceutical (SNTA) 0.34 $SNTA Synta An
Post# of 273258
Posted On: 09/02/2016 7:19:45 AM
Synta Pharmaceutical (SNTA) 0.34 $SNTA
Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal Pharmaceuticals
BusinessWire - Wed Jun 08, 3:15PM CDT
Synta Pharmaceuticals Corp. ("Synta"
(NASDAQ: SNTA) announced today that the annual meeting of stockholders to approve, among other things, the merger agreement with Madrigal Pharmaceuticals will be held on July 21, 2016, at 9:00 a.m. Eastern Time, for stockholders of record as of the close of business on May 31, 2016. The annual meeting will be held at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111.
SNTA: 0.34 (+0.07)
Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June
BusinessWire - Thu Jun 02, 6:00AM CDT
Synta Pharmaceuticals Corp. ("Synta" (NASDAQ:SNTA) today announced that Marc Schneebaum, Chief Financial Officer of Synta, will be joined by Paul Friedman, M.D., designated Chairman and Chief Executive Officer of Madrigal Pharmaceuticals, and Rebecca Taub, PhD, Founder and current Chief Executive Officer of Madrigal Pharmaceuticals, to present at the following upcoming investor conferences:
SNTA: 0.34 (+0.07)
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 1.36 (-0.05), SNTA: 0.34 (+0.07), CTIC: 0.39 (unch), LPTN: 2.37 (+0.02)
Synta (SNTA) Lowers Q1 Loss Y/Y, Focus on Madrigal Merger
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:13AM CDT
Synta Pharmaceuticals (SNTA) reported a first-quarter 2016 loss of 5 cents per share, much narrower than the year-ago loss of 19 cents.
SNTA: 0.34 (+0.07), ANIP: 61.42 (+1.68), RTRX: 16.35 (+0.33), BMY: 56.76 (-0.63)
What's in the Cards for Synta (SNTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 4:58AM CDT
Synta Pharmaceuticals (SNTA), which is expected to report first-quarter 2016 results on May 5, had posted a positive surprise of 21.52% last quarter.
IPXL: 23.94 (-0.25), SNTA: 0.34 (+0.07), JAZZ: 123.31 (-0.52), BIND: 0.78 (-0.09)
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen
MDVN: 80.93 (+0.37), OREX: 3.92 (-0.01), SNTA: 0.34 (+0.07), GILD: 77.42 (-0.96), ABBV: 64.03 (-0.07)
Biotech Stock Roundup: Medivation Buyout Rumors Resurface, Synta Up on Merger Deal
Arpita Dutt - Zacks Investment Research - Wed Apr 20, 3:38PM CDT
Will Medivation (MDVN) be the next biotech stock to be acquired?
MDVN: 80.93 (+0.37), OREX: 3.92 (-0.01), SNTA: 0.34 (+0.07), GILD: 77.42 (-0.96), SRPT: 26.56 (+0.49), AMGN: 170.13 (+0.07), ABBV: 64.03 (-0.07)
Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 10:30AM CDT
Synta (SNTA) announced all-stock merger transaction with Madrigal Pharmaceuticals to create a company focused on cardiovascular-metabolic diseases and NASH.
SNTA: 0.34 (+0.07), EBS: 26.41 (-0.24), ICPT: 146.82 (-1.49), AMAG: 23.71 (-0.12)
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
BusinessWire - Thu Apr 14, 6:00AM CDT
--- Paul A. Friedman, M.D. Named Chairman and Chief Executive Officer of Combined Company -
SNTA: 0.34 (+0.07)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.68 (-0.09), DRNA: 3.13 (-0.02), INCY: 80.81 (-0.29), LLY: 77.23 (-0.52), STML: 8.15 (-0.03), SNTA: 0.34 (+0.07), ANTH: 2.91 (+0.03), EXEL: 11.35 (+0.20)
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 170.13 (+0.07), ATRA: 19.85 (+0.31), STML: 8.15 (-0.03), SNTA: 0.34 (+0.07), ATNM: 1.76 (-0.04), SNDX: 13.94 (-0.24), BLCM: 17.47 (+0.25), BPTH: 1.58 (+0.05), TEVA: 50.90 (+0.51), AGIO: 36.74 (-0.10), XLRN: 30.25 (+0.24), ARRY: 3.52 (+0.09)
Malignant Mesothelioma Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/2dt2rm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malignant Mesothelioma Overview - Therapeutics Development - Pipeline Products for Malignant Mesothelioma - Overview - Pipeline Products for Malignant Mesothelioma - Comparative Analysis - Malignant Mesothelioma - Therapeutics under Development by Companies - Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes - Malignant Mesothelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malignant Mesothelioma - Products under Development by Companies - Malignant Mesothelioma - Products under Investigation by Universities/Institutes - Malignant Mesothelioma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Berg LLC - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Synta Pharmaceuticals Corp. - Targovax AS - TRACON Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2dt2rm/malignant
ADRO: 14.22 (+0.13), PFE: 34.68 (-0.12), LLY: 77.23 (-0.52), BMY: 56.76 (-0.63), EGRX: 59.02 (-0.73), GSK: 42.98 (-0.48), SNTA: 0.34 (+0.07), MRK: 62.90 (+0.11), AVEO: 0.91 (-0.02), TCON: 6.18 (-0.06), NVS: 78.27 (-0.50), FPRX: 44.74 (+0.76)
BUYINS.NET: FNGN, SNTA, FIG Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 30, 6:58AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Financial Engines Inc (NASDAQ:FNGN), Synta Pharmaceuticals Corp (NASDAQ:SNTA), Fortress Investment Group LLC (NYSE:FIG) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
SNTA: 0.34 (+0.07), FNGN: 31.96 (-0.01), FIG: 4.97 (+0.09)
4 Small Cap NASDAQ/NYSE Stocks Trading With Heavy Volume
ACCESSWIRE - Tue Dec 15, 6:00AM CST
NEW YORK, NY / ACCESSWIRE / December 15, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
SNTA: 0.34 (+0.07), FXCM: 9.25 (-0.08), STRP: 22.95 (-0.75)
Global Refractory Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015 - 50 Companies & 117 Drug Profiles
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5gtx2j/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - GlaxoSmithKline Plc - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NantKwest, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Oxford BioTherapeutics Ltd - Synta Pharmaceuticals Corp. - TaiGen Biotechnology Co., Ltd. - Threshold Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/5g...tory_acute
MGNX: 30.05 (+0.24), AMGN: 170.13 (+0.07), EPZM: 7.31 (unch), GSK: 42.98 (-0.48), BMY: 56.76 (-0.63), CTIC: 0.39 (unch), SNTA: 0.34 (+0.07), ATNM: 1.76 (-0.04), MRK: 62.90 (+0.11), AZN: 32.60 (-0.21), AVEO: 0.91 (-0.02), CALA: 3.08 (-0.02), ABBV: 64.03 (-0.07), AGIO: 36.74 (-0.10), NVS: 78.27 (-0.50), KPTI: 11.10 (+1.15), CELGZ: 1.13 (-0.03)
World Malignant Pleural Mesothelioma Therapeutics Pipeline Report H2 2015 - 32 Companies & 40 Drug Profiles
M2 - Mon Dec 14, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/4n84qr/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Amphera BV - AnGes MG, Inc. - ArQule, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CanBas Co., Ltd. - Concordia Healthcare Corp. - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - Juno Therapeutics Inc. - MedImmune, LLC - Merck & Co., Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Polaris Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. - Virttu Biologics Limited Drug Profiles - Ad5-SGE-REIC/Dkk3 - amatuximab - anetumab ravtansine - ascrinvacumab - bevacizumab - BG-00001 - BMS-986148 - BNC-105 - CBP-501 - Cell Therapy 1 for Oncology - Cell Therapy for Malignant Pleural Mesothelioma and Advanced Leukemia - CRS-207 - FP-1039 - ganetespib - GEN-0101 - Gene Therapy for Malignant Pleural Mesothelioma - Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - GLONC-1 - GSK-2256098 - HSV-1716 - iCasp9M28z - JTCR-016 - MesoCancerVac - MesoCART - Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - napabucasin - NGR-hTNF - nintedanib - nivolumab - pegargiminase - pembrolizumab - porfimer sodium - rAd-IFN - Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer - TargomiRs For more information visit http://www.researchandmarkets.com/research/4n...nt_pleural
ADRO: 14.22 (+0.13), PFE: 34.68 (-0.12), ARQL: 1.40 (-0.08), BMY: 56.76 (-0.63), GSK: 42.98 (-0.48), VSTM: 1.34 (-0.01), SNTA: 0.34 (+0.07), MRK: 62.90 (+0.11), JUNO: 29.29 (-0.29), NVS: 78.27 (-0.50), CXRX: 8.43 (-0.28), FPRX: 44.74 (+0.76)
Relapsed Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5bkxtd/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline Plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Novartis AG - Polaris Pharmaceuticals, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/5b...psed_acute
MGNX: 30.05 (+0.24), INCY: 80.81 (-0.29), AMGN: 170.13 (+0.07), GSK: 42.98 (-0.48), BMY: 56.76 (-0.63), CTIC: 0.39 (unch), VSTM: 1.34 (-0.01), SNTA: 0.34 (+0.07), ATNM: 1.76 (-0.04), MRK: 62.90 (+0.11), AZN: 32.60 (-0.21), CALA: 3.08 (-0.02), ABBV: 64.03 (-0.07), AGIO: 36.74 (-0.10), NVS: 78.27 (-0.50), KPTI: 11.10 (+1.15), EXEL: 11.35 (+0.20), CELGZ: 1.13 (-0.03)
Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 with AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche & Pfizer Dominating
M2 - Thu Nov 12, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4z56z7/global_nonsmall) has announced the addition of the "Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering. The global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019. The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer. The report includes a discussion of the key vendors operating in this market. The non-small cell lung cancer therapeutics market in China grew exponentially in 2014. The markets in Australia, India, and Japan are expected to witness considerable growth during the forecast period. According to the report, current therapies available to treat non-small cell lung cancer do not provide a permanent cure, and approaches such as non-selective cytotoxic chemotherapy tend to cause toxicity in patients. Further, the report states that the increase in personalized therapies will lead to the fragmentation of the global non-small cell lung cancer market, thus presenting a major threat to this market. Key vendors - AstraZeneca - Celgene - Eli Lilly - F. Hoffmann-La Roche - Pfizer Other prominent vendors - Abbvie - Aetna - Agennix - Amgen - BetaPharma - Bionumerik Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - CBT Pharma - Celldex Therapeutics - Dainippon Pharma - Eisai Pharmaceuticals - GlaxoSmithKline - Helsinn - IMClone Systems - IsisPharma - Kadmon - Kyowa Hakko Kirin - MabVax Therapeutics - Merck - Novartis - OncoGenex - OSI Pharmaceuticals - Peregrine - Pierre Fabre - Qiagen - Sanofi - Synta Pharmaceuticals - Teva Pharmaceuticals Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Product profiles Part 05: Introduction Part 06: Disease overview Part 07: Pipeline portfolio Part 08: Market landscape Part 09: Market segmentation by molecule type Part 10: Market segmentation by route of administration Part 11: Geographical segmentation Part 12: Market drivers Part 13: Impact of drivers Part 14: Market challenges Part 15: Impact of drivers and challenges Part 16: Market trends Part 17: Vendor landscape Part 18: Key vendor analysis Part 19: Appendix For more information visit http://www.researchandmarkets.com/research/4z...l_nonsmall
SNTA: 0.34 (+0.07), MRK: 62.90 (+0.11), CLDX: 3.36 (+0.04), AMGN: 170.13 (+0.07), LLY: 77.23 (-0.52), GSK: 42.98 (-0.48), BMY: 56.76 (-0.63), NVS: 78.27 (-0.50), CELGZ: 1.13 (-0.03)
Synta Reports Third Quarter 2015 Financial Results
BusinessWire - Thu Nov 05, 4:20PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its business strategy.
SNTA: 0.34 (+0.07)
Synta (SNTA) Q3 Earnings Preview: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Nov 03, 3:45PM CST
Synta Pharmaceuticals Corp. (SNTA) is expected to report third-quarter 2015 results on Nov 5.
MACK: 4.59 (-0.03), SNTA: 0.34 (+0.07), ALNY: 69.02 (-0.83), SNY: 38.41 (-0.06)
Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal Pharmaceuticals
BusinessWire - Wed Jun 08, 3:15PM CDT
Synta Pharmaceuticals Corp. ("Synta"
(NASDAQ: SNTA) announced today that the annual meeting of stockholders to approve, among other things, the merger agreement with Madrigal Pharmaceuticals will be held on July 21, 2016, at 9:00 a.m. Eastern Time, for stockholders of record as of the close of business on May 31, 2016. The annual meeting will be held at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111. SNTA: 0.34 (+0.07)
Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June
BusinessWire - Thu Jun 02, 6:00AM CDT
Synta Pharmaceuticals Corp. ("Synta"
(NASDAQ:SNTA) today announced that Marc Schneebaum, Chief Financial Officer of Synta, will be joined by Paul Friedman, M.D., designated Chairman and Chief Executive Officer of Madrigal Pharmaceuticals, and Rebecca Taub, PhD, Founder and current Chief Executive Officer of Madrigal Pharmaceuticals, to present at the following upcoming investor conferences: SNTA: 0.34 (+0.07)
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 1.36 (-0.05), SNTA: 0.34 (+0.07), CTIC: 0.39 (unch), LPTN: 2.37 (+0.02)
Synta (SNTA) Lowers Q1 Loss Y/Y, Focus on Madrigal Merger
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:13AM CDT
Synta Pharmaceuticals (SNTA) reported a first-quarter 2016 loss of 5 cents per share, much narrower than the year-ago loss of 19 cents.
SNTA: 0.34 (+0.07), ANIP: 61.42 (+1.68), RTRX: 16.35 (+0.33), BMY: 56.76 (-0.63)
What's in the Cards for Synta (SNTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 4:58AM CDT
Synta Pharmaceuticals (SNTA), which is expected to report first-quarter 2016 results on May 5, had posted a positive surprise of 21.52% last quarter.
IPXL: 23.94 (-0.25), SNTA: 0.34 (+0.07), JAZZ: 123.31 (-0.52), BIND: 0.78 (-0.09)
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen
MDVN: 80.93 (+0.37), OREX: 3.92 (-0.01), SNTA: 0.34 (+0.07), GILD: 77.42 (-0.96), ABBV: 64.03 (-0.07)
Biotech Stock Roundup: Medivation Buyout Rumors Resurface, Synta Up on Merger Deal
Arpita Dutt - Zacks Investment Research - Wed Apr 20, 3:38PM CDT
Will Medivation (MDVN) be the next biotech stock to be acquired?
MDVN: 80.93 (+0.37), OREX: 3.92 (-0.01), SNTA: 0.34 (+0.07), GILD: 77.42 (-0.96), SRPT: 26.56 (+0.49), AMGN: 170.13 (+0.07), ABBV: 64.03 (-0.07)
Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 10:30AM CDT
Synta (SNTA) announced all-stock merger transaction with Madrigal Pharmaceuticals to create a company focused on cardiovascular-metabolic diseases and NASH.
SNTA: 0.34 (+0.07), EBS: 26.41 (-0.24), ICPT: 146.82 (-1.49), AMAG: 23.71 (-0.12)
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
BusinessWire - Thu Apr 14, 6:00AM CDT
--- Paul A. Friedman, M.D. Named Chairman and Chief Executive Officer of Combined Company -
SNTA: 0.34 (+0.07)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.68 (-0.09), DRNA: 3.13 (-0.02), INCY: 80.81 (-0.29), LLY: 77.23 (-0.52), STML: 8.15 (-0.03), SNTA: 0.34 (+0.07), ANTH: 2.91 (+0.03), EXEL: 11.35 (+0.20)
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 170.13 (+0.07), ATRA: 19.85 (+0.31), STML: 8.15 (-0.03), SNTA: 0.34 (+0.07), ATNM: 1.76 (-0.04), SNDX: 13.94 (-0.24), BLCM: 17.47 (+0.25), BPTH: 1.58 (+0.05), TEVA: 50.90 (+0.51), AGIO: 36.74 (-0.10), XLRN: 30.25 (+0.24), ARRY: 3.52 (+0.09)
Malignant Mesothelioma Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/2dt2rm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malignant Mesothelioma Overview - Therapeutics Development - Pipeline Products for Malignant Mesothelioma - Overview - Pipeline Products for Malignant Mesothelioma - Comparative Analysis - Malignant Mesothelioma - Therapeutics under Development by Companies - Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes - Malignant Mesothelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malignant Mesothelioma - Products under Development by Companies - Malignant Mesothelioma - Products under Investigation by Universities/Institutes - Malignant Mesothelioma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Berg LLC - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Synta Pharmaceuticals Corp. - Targovax AS - TRACON Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2dt2rm/malignant
ADRO: 14.22 (+0.13), PFE: 34.68 (-0.12), LLY: 77.23 (-0.52), BMY: 56.76 (-0.63), EGRX: 59.02 (-0.73), GSK: 42.98 (-0.48), SNTA: 0.34 (+0.07), MRK: 62.90 (+0.11), AVEO: 0.91 (-0.02), TCON: 6.18 (-0.06), NVS: 78.27 (-0.50), FPRX: 44.74 (+0.76)
BUYINS.NET: FNGN, SNTA, FIG Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 30, 6:58AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Financial Engines Inc (NASDAQ:FNGN), Synta Pharmaceuticals Corp (NASDAQ:SNTA), Fortress Investment Group LLC (NYSE:FIG) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
SNTA: 0.34 (+0.07), FNGN: 31.96 (-0.01), FIG: 4.97 (+0.09)
4 Small Cap NASDAQ/NYSE Stocks Trading With Heavy Volume
ACCESSWIRE - Tue Dec 15, 6:00AM CST
NEW YORK, NY / ACCESSWIRE / December 15, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
SNTA: 0.34 (+0.07), FXCM: 9.25 (-0.08), STRP: 22.95 (-0.75)
Global Refractory Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015 - 50 Companies & 117 Drug Profiles
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5gtx2j/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - GlaxoSmithKline Plc - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NantKwest, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Oxford BioTherapeutics Ltd - Synta Pharmaceuticals Corp. - TaiGen Biotechnology Co., Ltd. - Threshold Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/5g...tory_acute
MGNX: 30.05 (+0.24), AMGN: 170.13 (+0.07), EPZM: 7.31 (unch), GSK: 42.98 (-0.48), BMY: 56.76 (-0.63), CTIC: 0.39 (unch), SNTA: 0.34 (+0.07), ATNM: 1.76 (-0.04), MRK: 62.90 (+0.11), AZN: 32.60 (-0.21), AVEO: 0.91 (-0.02), CALA: 3.08 (-0.02), ABBV: 64.03 (-0.07), AGIO: 36.74 (-0.10), NVS: 78.27 (-0.50), KPTI: 11.10 (+1.15), CELGZ: 1.13 (-0.03)
World Malignant Pleural Mesothelioma Therapeutics Pipeline Report H2 2015 - 32 Companies & 40 Drug Profiles
M2 - Mon Dec 14, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/4n84qr/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Amphera BV - AnGes MG, Inc. - ArQule, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CanBas Co., Ltd. - Concordia Healthcare Corp. - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - Juno Therapeutics Inc. - MedImmune, LLC - Merck & Co., Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Polaris Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. - Virttu Biologics Limited Drug Profiles - Ad5-SGE-REIC/Dkk3 - amatuximab - anetumab ravtansine - ascrinvacumab - bevacizumab - BG-00001 - BMS-986148 - BNC-105 - CBP-501 - Cell Therapy 1 for Oncology - Cell Therapy for Malignant Pleural Mesothelioma and Advanced Leukemia - CRS-207 - FP-1039 - ganetespib - GEN-0101 - Gene Therapy for Malignant Pleural Mesothelioma - Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - GLONC-1 - GSK-2256098 - HSV-1716 - iCasp9M28z - JTCR-016 - MesoCancerVac - MesoCART - Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - napabucasin - NGR-hTNF - nintedanib - nivolumab - pegargiminase - pembrolizumab - porfimer sodium - rAd-IFN - Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer - TargomiRs For more information visit http://www.researchandmarkets.com/research/4n...nt_pleural
ADRO: 14.22 (+0.13), PFE: 34.68 (-0.12), ARQL: 1.40 (-0.08), BMY: 56.76 (-0.63), GSK: 42.98 (-0.48), VSTM: 1.34 (-0.01), SNTA: 0.34 (+0.07), MRK: 62.90 (+0.11), JUNO: 29.29 (-0.29), NVS: 78.27 (-0.50), CXRX: 8.43 (-0.28), FPRX: 44.74 (+0.76)
Relapsed Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5bkxtd/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline Plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Novartis AG - Polaris Pharmaceuticals, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/5b...psed_acute
MGNX: 30.05 (+0.24), INCY: 80.81 (-0.29), AMGN: 170.13 (+0.07), GSK: 42.98 (-0.48), BMY: 56.76 (-0.63), CTIC: 0.39 (unch), VSTM: 1.34 (-0.01), SNTA: 0.34 (+0.07), ATNM: 1.76 (-0.04), MRK: 62.90 (+0.11), AZN: 32.60 (-0.21), CALA: 3.08 (-0.02), ABBV: 64.03 (-0.07), AGIO: 36.74 (-0.10), NVS: 78.27 (-0.50), KPTI: 11.10 (+1.15), EXEL: 11.35 (+0.20), CELGZ: 1.13 (-0.03)
Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 with AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche & Pfizer Dominating
M2 - Thu Nov 12, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4z56z7/global_nonsmall) has announced the addition of the "Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering. The global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019. The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer. The report includes a discussion of the key vendors operating in this market. The non-small cell lung cancer therapeutics market in China grew exponentially in 2014. The markets in Australia, India, and Japan are expected to witness considerable growth during the forecast period. According to the report, current therapies available to treat non-small cell lung cancer do not provide a permanent cure, and approaches such as non-selective cytotoxic chemotherapy tend to cause toxicity in patients. Further, the report states that the increase in personalized therapies will lead to the fragmentation of the global non-small cell lung cancer market, thus presenting a major threat to this market. Key vendors - AstraZeneca - Celgene - Eli Lilly - F. Hoffmann-La Roche - Pfizer Other prominent vendors - Abbvie - Aetna - Agennix - Amgen - BetaPharma - Bionumerik Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - CBT Pharma - Celldex Therapeutics - Dainippon Pharma - Eisai Pharmaceuticals - GlaxoSmithKline - Helsinn - IMClone Systems - IsisPharma - Kadmon - Kyowa Hakko Kirin - MabVax Therapeutics - Merck - Novartis - OncoGenex - OSI Pharmaceuticals - Peregrine - Pierre Fabre - Qiagen - Sanofi - Synta Pharmaceuticals - Teva Pharmaceuticals Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Product profiles Part 05: Introduction Part 06: Disease overview Part 07: Pipeline portfolio Part 08: Market landscape Part 09: Market segmentation by molecule type Part 10: Market segmentation by route of administration Part 11: Geographical segmentation Part 12: Market drivers Part 13: Impact of drivers Part 14: Market challenges Part 15: Impact of drivers and challenges Part 16: Market trends Part 17: Vendor landscape Part 18: Key vendor analysis Part 19: Appendix For more information visit http://www.researchandmarkets.com/research/4z...l_nonsmall
SNTA: 0.34 (+0.07), MRK: 62.90 (+0.11), CLDX: 3.36 (+0.04), AMGN: 170.13 (+0.07), LLY: 77.23 (-0.52), GSK: 42.98 (-0.48), BMY: 56.76 (-0.63), NVS: 78.27 (-0.50), CELGZ: 1.13 (-0.03)
Synta Reports Third Quarter 2015 Financial Results
BusinessWire - Thu Nov 05, 4:20PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its business strategy.
SNTA: 0.34 (+0.07)
Synta (SNTA) Q3 Earnings Preview: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Nov 03, 3:45PM CST
Synta Pharmaceuticals Corp. (SNTA) is expected to report third-quarter 2015 results on Nov 5.
MACK: 4.59 (-0.03), SNTA: 0.34 (+0.07), ALNY: 69.02 (-0.83), SNY: 38.41 (-0.06)
(0)
(0)Scroll down for more posts ▼